Published May 2, 2026 | Version v1

Approval Process of Investigational New Drugs Application for Chemotherapeutics Drugs in INDIA (CDSCO) Comparison with USA (USFDA) & EUROPE (EMA)

Description

A crucial stage in the worldwide drug development process is the acceptance of Investigational New Drug (IND) applications for chemotherapeutic agents, which guarantees the quality, safety, and effectiveness of cancer treatments prior to human clinical trials. The United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the Central Drugs Standard Control Organization (CDSCO) have established structured frameworks for IND approval; however, there are notable variations in the regulatory pathways, documentation requirements, and review timelines. The New Drugs and Clinical Trials Rules, 2019, which govern IND applications in India, mandate the submission of preclinical data, clinical trial protocols, and manufacturing information. Subject Expert Committees and regulatory agencies then evaluate the applications. ([CDSCO]) The USFDA, on the other hand, requires IND filing before clinical trials, with a specific review time prior to trial beginning and a focus on comprehensive pharmacological, toxicological, and clinical study protocols. ([PMC]) In order to ensure uniform evaluation among EU member states, the EMA uses a Clinical Trial Application (CTA) system under a centralized or decentralized method.

Files

13-Bhagwat Deshmukh.pdf

Files (4.3 MB)

Name Size
md5:db488b0fa640408fe30f9e8b4866781d
4.3 MB Preview Download